TAE Life Sciences (TLS) products

Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the availability of better boron-10 compounds and access to a neutron source posed a significant barrier to clinical research and adoption of BNCT as a practical cancer therapy.